Lustig Marc 4
4 · BriaCell Therapeutics Corp. · Filed May 20, 2024
Insider Transaction Report
Form 4
Lustig Marc
Director
Transactions
- Purchase
Common Stock Warrants
2024-05-14+902,935→ 902,935 total(indirect: By L5 Capital Inc.)Exercise: $2.11→ Common Stock (902,935 underlying) - Purchase
Common Shares
2024-05-14$2.21/sh+902,935$2,000,001→ 2,542,935 total(indirect: By L5 Capital Inc.)
Footnotes (1)
- [F1]The common shares and warrants reported on this Form 4 were purchased by L5 Capital Inc. in an offering at a combined purchase price of $2.215 per common share and accompanying warrant, for an aggregate purchase price of $2,000,000 pursuant to a securities purchase agreement dated May 14, 2024. The warrants will be exercisable six months from the date of issuance at an exercise price of $2.11 and will expire on the five year anniversary of the initial exercise date. L5 Capital Inc. is controlled by the Reporting Person, Marc Lustig, a director of the Issuer.